Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Albireo Pharma stock

Own Albireo Pharma stock in just a few minutes.

Albireo Pharma, Inc is a biotechnology business based in the US. Albireo Pharma shares (ALBO) are listed on the NASDAQ and all prices are listed in US Dollars. Albireo Pharma employs 90 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Albireo Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALBO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Albireo Pharma share price

Use our graph to track the performance of ALBO stocks over time.

Albireo Pharma shares at a glance

Information last updated 2021-04-30.
52-week range$20.68 - $43.44
50-day moving average $33.93
200-day moving average $36.14
Wall St. target price$73.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.23

Buy Albireo Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Albireo Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Albireo Pharma financials

Revenue TTM $8.3 million
Gross profit TTM $8.3 million
Return on assets TTM -26.7%
Return on equity TTM -78.45%
Profit margin 0%
Book value $9.49
Market capitalisation $616.4 million

TTM: trailing 12 months

Shorting Albireo Pharma shares

There are currently 1.9 million Albireo Pharma shares held short by investors – that's known as Albireo Pharma's "short interest". This figure is 11.6% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Albireo Pharma shares can be evaluated.

Albireo Pharma's "short interest ratio" (SIR)

Albireo Pharma's "short interest ratio" (SIR) is the quantity of Albireo Pharma shares currently shorted divided by the average quantity of Albireo Pharma shares traded daily (recently around 149316.21187801). Albireo Pharma's SIR currently stands at 12.46. In other words for every 100,000 Albireo Pharma shares traded daily on the market, roughly 12460 shares are currently held short.

However Albireo Pharma's short interest can also be evaluated against the total number of Albireo Pharma shares, or, against the total number of tradable Albireo Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Albireo Pharma's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Albireo Pharma shares in existence, roughly 100 shares are currently held short) or 0.1075% of the tradable shares (for every 100,000 tradable Albireo Pharma shares, roughly 108 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Albireo Pharma.

Find out more about how you can short Albireo Pharma stock.

Albireo Pharma share dividends

We're not expecting Albireo Pharma to pay a dividend over the next 12 months.

Have Albireo Pharma's shares ever split?

Albireo Pharma's shares were split on a 1:30 basis on 3 November 2016. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Albireo Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Albireo Pharma shares which in turn could have impacted Albireo Pharma's share price.

Albireo Pharma share price volatility

Over the last 12 months, Albireo Pharma's shares have ranged in value from as little as $20.68 up to $43.44. A popular way to gauge a stock's volatility is its "beta".

ALBO.US volatility(beta: 1.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Albireo Pharma's is 1.5896. This would suggest that Albireo Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Albireo Pharma overview

Albireo Pharma, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co. , Ltd. for the development and commercialization of elobixibat.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site